Skip to content
Fear and GreedStocks35Crypto24
Start for free

Adaptive Biotechnologies stock

ADPTNASDAQ

Adaptive Biotechnologies Corporation, HealthcareISIN US00650F1093

$29.48▼ $0.46 (−1.5%)Closing price of 12 Nov 2026

47Score 47 out of 100, Weak

Turn on early warning

Price and trend

85 / 100

Price history

+103% in one year

The chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.

Long-term trend

Above the 200-day line: the price is 47% above it.

Trend change

Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.

Momentum

Normal: the price is neither overheated nor sold off (RSI 65).

Distance to the high

The price is 2.6% below its 52-week high. Largest decline in 7 years: 97% (January 2021 to April 2024).

Chart figures for advanced users
SMA 50$26.82
Average price of the last 50 trading days, shows the short-term trend.
SMA 200$20.03
Average price of the last 200 trading days, shows the long-term trend.
RSI (14)65
Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
MACDabove the signal line
Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
Support$12.41
The lowest closing price of the last twelve months.
Resistance$30.26
The highest closing price of the last twelve months.
What would $1,000 in Adaptive Biotechnologies have become?Return triangle for Adaptive Biotechnologies
Market cap
$4.85B
Div. yield
no dividend
Loss
Loss expected
Fair value
no data

Snapshot

Computed from the data by fixed rules, no AI

  • Adaptive Biotechnologies Corporation belongs to the Biotechnology industry (United States) and, with a market value of $4.77B, is number 78 of 296 companies in its industry on MEQIRI.
  • In fiscal 2025 it reported revenue of $276.98M (up 54.8% year on year) and a loss of $59.5M.
  • For fiscal 2026, analysts expect on average revenue of $293.24M (up 5.9%) and adjusted earnings per share of −$0.54.
Show more
  • MEQIRI Score 47 out of 100 (Weak): rank 418 of 714 in Healthcare, median 53.

In plain words

The numbers on this page in plain words, written by an AI

Strengths

None of our strength checks applies.

Weaknesses

  • High debtDebt 2.22 times equity (latest quarter), Biotechnology median 0.09.Stability 32
  • Loss-makingLoss of $70.52M over the last 12 months.Fundamentals 17
  • Negative free cash flowFree cash flow −$8.82M over the last 12 months.Fundamentals 17
47/ 100
MEQIRI Score
Weak

Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.

Daily figure as of 12 Nov 2026

How the score is calculated

Score overview

Fundamental quality fluctuates.

Profit consistency0% of years
Cash conversion (free cash flow to earnings, 12 months)not measured
ROIC (12 months)−19.6%
Positive free cash flow11% of years
How this category is measured

Score history

The full history of up to 20 years comes with MEQIRI Pro.

See plans

Valuation

Valuation signal

not measured
Price
$29.94
Fair value
not meaningful
Gap to fair value
no data

Closing price of 11 Nov 2026, used by the daily score.

A fair value is not meaningful here, so the signal follows the valuation grade.

Valuation metrics

no data
no data
Fair value (model)
no data

The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.

Calculate with your own assumptions

Company performance

This shows several years of history with an automatic assessment.

Revenue

9 years

In the twelve months to 30 Sep 2026, revenue rose 17.9% on the twelve months before. Revenue has grown strongly since 2017, at around 28% per year.

Margins

9 years
  • Gross margin
  • Operating margin
  • Net margin

In fiscal 2025: gross 74%, operating −21%, net −21%.

Debt & balance sheet

latest quarter
2.22
−4x
3.97
Cash & equivalents
$298.95M

Debt is elevated. Keep an eye on the interest burden and refinancing.

Earnings

Next earnings
4 Feb 2027in 84 days
Last reported
4 Nov 2026EPS reported $0.02 (expected −$0.09)above expectations

Analyst estimates

Analysts have cut their 2027 earnings estimate by 3.6% since 15 Oct 2026. Falling estimates often precede bad news.

Fiscal 20266 analysts
Earnings per share
−$0.54+0.7%
Revenue
$293.24M−0.1%
Fiscal 20276 analysts
Earnings per share
−$0.17−3.6%
Revenue
$360.11M+0.3%

MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.

Company outlook raised

Share price after the results: −0.5%

Full year MRD revenue guidance raised to $260 million to $270 million (from $255 million to $265 million), volume growth of at least 35% expected.

Supporting passage from the call, verbatim
“We are raising our full year MRD revenue guidance to a range of $260 million to $270 million, up from our prior range of $255 million to $265 million. This increase reflects stronger-than-expected clinical volume performance in the first quarter and continued momentum across key growth drivers.”

The outlook is not part of the score and not a recommendation to buy or sell.

From the earnings call on 5 May 2026 (fiscal Q1 2026), read by AI.

Insiders

Open-market purchases and sales by executives, board members and major holders

All insider purchases

No open-market purchases in the last 6 months. 11 insiders sold, $63.98M in total.

Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.

  • Rubinstein JulieSale

    10 Nov 2026, President and COO

    Shares
    11,881
    Price
    $29.52
    Value
    $350,721
  • Rubinstein JulieSale

    9 Nov 2026, President and COO

    Shares
    11,881
    Price
    $30.12
    Value
    $357,836
  • Rubinstein JulieSale

    6 Nov 2026, President and COO

    Shares
    11,881
    Price
    $27.48
    Value
    $326,538
Show 54 more
  • Rubinstein JulieSale

    5 Nov 2026, President and COO

    Shares
    11,881
    Price
    $26.53
    Value
    $315,149
  • Rubinstein JulieSale

    4 Nov 2026, President and COO

    Shares
    11,881
    Price
    $26.32
    Value
    $312,755
  • Rubinstein JulieSale

    3 Nov 2026, President and COO

    Shares
    11,881
    Price
    $25.98
    Value
    $308,668
  • Rubinstein JulieSale

    2 Nov 2026, President and COO

    Shares
    11,881
    Price
    $25.47
    Value
    $302,627
  • Rubinstein JulieSale

    30 Oct 2026, President and COO

    Shares
    11,881
    Price
    $26.73
    Value
    $317,596
  • Rubinstein JulieSale

    29 Oct 2026, President and COO

    Shares
    11,881
    Price
    $28.27
    Value
    $335,876
  • Rubinstein JulieSale

    28 Oct 2026, President and COO

    Shares
    11,881
    Price
    $28.45
    Value
    $337,988
  • Rubinstein JulieSale

    27 Oct 2026, President and COO

    Shares
    11,881
    Price
    $27.29
    Value
    $324,234
  • Rubinstein JulieSale

    26 Oct 2026, President and COO

    Shares
    11,881
    Price
    $26.04
    Value
    $309,409
  • Rubinstein JulieSale

    23 Oct 2026, President and COO

    Shares
    11,881
    Price
    $24.98
    Value
    $296,842
  • Rubinstein JulieSale

    22 Oct 2026, President and COO

    Shares
    11,881
    Price
    $24.51
    Value
    $291,206
  • Rubinstein JulieSale

    21 Oct 2026, President and COO

    Shares
    11,881
    Price
    $25.41
    Value
    $301,877
  • Rubinstein JulieSale

    20 Oct 2026, President and COO

    Shares
    11,881
    Price
    $24.53
    Value
    $291,473
  • Rubinstein JulieSale

    19 Oct 2026, President and COO

    Shares
    11,881
    Price
    $24.05
    Value
    $285,738
  • Rubinstein JulieSale

    16 Oct 2026, President and COO

    Shares
    11,881
    Price
    $24.24
    Value
    $288,011
  • Rubinstein JulieSale

    15 Oct 2026, President and COO

    Shares
    11,881
    Price
    $25.61
    Value
    $304,272
  • Rubinstein JulieSale

    14 Oct 2026, President and COO

    Shares
    11,881
    Price
    $25.68
    Value
    $305,072
  • Rubinstein JulieSale

    13 Oct 2026, President and COO

    Shares
    11,881
    Price
    $25.50
    Value
    $302,966
  • Rubinstein JulieSale

    12 Oct 2026, President and COO

    Shares
    11,881
    Price
    $25.51
    Value
    $303,127
  • Rubinstein JulieSale

    9 Oct 2026, President and COO

    Shares
    11,881
    Price
    $26.41
    Value
    $313,777
  • Rubinstein JulieSale

    8 Oct 2026, President and COO

    Shares
    11,881
    Price
    $25.66
    Value
    $304,866
  • Rubinstein JulieSale

    7 Oct 2026, President and COO

    Shares
    11,881
    Price
    $26.40
    Value
    $313,658
  • Rubinstein JulieSale

    6 Oct 2026, President and COO

    Shares
    11,881
    Price
    $27.75
    Value
    $329,698
  • Bobulsky SusanSale

    6 Oct 2026, Chief Commercial Officer, MRD

    Shares
    6,444
    Price
    $30.00
    Value
    $193,320
  • Rubinstein JulieSale

    5 Oct 2026, President and COO

    Shares
    11,881
    Price
    $29.19
    Value
    $346,815
  • Rubinstein JulieSale

    2 Oct 2026, President and COO

    Shares
    11,881
    Price
    $28.13
    Value
    $334,213
  • Rubinstein JulieSale

    1 Oct 2026, President and COO

    Shares
    11,881
    Price
    $28.05
    Value
    $333,301
  • Lo FrancisSale

    1 Oct 2026, Chief People Officer

    Shares
    26,792
    Price
    $28.28
    Value
    $757,697
  • Lo FrancisSale

    16 Sept 2026, Chief People Officer

    Shares
    115,406
    Price
    $28.06
    Value
    $3.24M
  • Bobulsky SusanSale

    15 Sept 2026, Chief Commercial Officer, MRD

    Shares
    1,195
    Price
    $27.00
    Value
    $32,265
  • Owen Katey EinterzSale

    26 Aug 2026, Board

    Shares
    9,615
    Price
    $26.00
    Value
    $249,990
  • Hershberg RobertSale

    18 Aug 2026, Board

    Shares
    30,664
    Price
    $24.40
    Value
    $748,208
  • Robins Chad MSale

    18 Aug 2026, CEO and Chairman

    Shares
    278,676
    Price
    $24.48
    Value
    $6.82M
  • Robins Chad MSale

    17 Aug 2026, CEO and Chairman

    Shares
    321,324
    Price
    $25.08
    Value
    $8.06M
  • Neupert Peter MSale

    17 Aug 2026, Board

    Shares
    124,690
    Price
    $25.15
    Value
    $3.14M
  • Bobulsky SusanSale

    10 Aug 2026, Chief Commercial Officer, MRD

    Shares
    3,000
    Price
    $25.00
    Value
    $75,000
  • Bobulsky SusanSale

    30 Jul 2026, Chief Commercial Officer, MRD

    Shares
    1,299
    Price
    $24.00
    Value
    $31,176
  • Robins Harlan SSale

    21 Jul 2026, Chief Scientific Officer

    Shares
    492,400
    Price
    $21.89
    Value
    $10.78M
  • Bobulsky SusanSale

    16 Jul 2026, Chief Commercial Officer, MRD

    Shares
    5,000
    Price
    $23.00
    Value
    $115,000
  • Lo FrancisSale

    15 Jul 2026, Chief People Officer

    Shares
    105,762
    Price
    $22.59
    Value
    $2.39M
  • Robins Harlan SSale

    2 Jul 2026, Chief Scientific Officer

    Shares
    386,240
    Price
    $22.01
    Value
    $8.5M
  • Lo FrancisSale

    2 Jul 2026, Chief People Officer

    Shares
    44,838
    Price
    $22.59
    Value
    $1.01M
  • Lo FrancisSale

    1 Jul 2026, Chief People Officer

    Shares
    51,004
    Price
    $22.45
    Value
    $1.14M
  • Bobulsky SusanSale

    1 Jul 2026, Chief Commercial Officer, MRD

    Shares
    487
    Price
    $22.00
    Value
    $10,714
  • Benzeno SharonSale

    29 Jun 2026, Chief Commercial Ofc Imm Med

    Shares
    154,768
    Price
    $21.14
    Value
    $3.27M
  • Benzeno SharonSale

    26 Jun 2026, Chief Commercial Ofc Imm Med

    Shares
    11,034
    Price
    $21.00
    Value
    $231,714
  • Bobulsky SusanSale

    25 Jun 2026, Chief Commercial Officer, MRD

    Shares
    5,000
    Price
    $20.50
    Value
    $102,500
  • Griffin Michelle ReneeSale

    25 Jun 2026, Board

    Shares
    52,084
    Price
    $20.18
    Value
    $1.05M
  • Robins Harlan SSale

    16 Jun 2026, Chief Scientific Officer

    Shares
    6,160
    Price
    $18.01
    Value
    $110,942
  • Robins Harlan SSale

    15 Jun 2026, Chief Scientific Officer

    Shares
    100,000
    Price
    $17.37
    Value
    $1.74M
  • Bobulsky SusanSale

    11 Jun 2026, Chief Commercial Officer, MRD

    Shares
    5,000
    Price
    $19.00
    Value
    $95,000
  • Lo FrancisSale

    4 Jun 2026, Chief People Officer

    Shares
    39,741
    Price
    $17.49
    Value
    $695,070
  • Bobulsky SusanSale

    4 Jun 2026, Chief Commercial Officer, MRD

    Shares
    11,000
    Price
    $18.00
    Value
    $198,000
  • Piskel KyleSale

    18 May 2026, Chief Financial Officer

    Shares
    3,115
    Price
    $13.04
    Value
    $40,620

Partial trades from one filing are shown in one row, with the average price.

Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.

What happened at Adaptive Biotechnologies

The key events of the last six months from our own data. A click takes you to the matching card.

Sector comparison

714 rated companies in Healthcare

Rank 418 of 714
418/ 714
This company
47
Sector median
53

Categories against the sector medianMedian of 714 companies

Profitability25 (median 37)12 below the median
Growth70 (median 53)17 above the median
Fundamentals17 (median 46)29 below the median
Stability32 (median 67)35 below the median
Capital allocation18 (median 39)21 below the median
Technical analysis85 (median 70)15 above the median
Momentum96 (median 71)25 above the median

The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.

Competitors in Biotechnology

The next larger and next smaller companies by market value

All 296 Biotechnology stocks

ETFs that hold Adaptive Biotechnologies

Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.

ETFWeightCostFund size
L&G Healthcare Technology & Innovation UCITS ETFXMLH2.05%0.49%€318.39M
Harbor Health Care UCITS ETF AccW3110.66%0.89%€11.61M
iShares Healthcare Innovation UCITS ETF2B780.42%0.40%€1.49B
Show 5 more
iShares Nasdaq US Biotechnology UCITS ETF2B700.28%0.35%€1.21B
Xtrackers Russell 2000 UCITS ETF 1CXRS20.16%0.30%€2.17B
State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR0.15%0.30%€4.22B
L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ0.15%0.30%€185.82M
iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG0.04%0.43%€2.48B

Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).

Data status and sources

Score
Daily value of 12 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Original filings at the SECReport a data error

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 21 Feb 2025)
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
Full disclosures, methodology and data sourcesAll ratings of the last 12 monthsHow the score is calculated

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy